 HOUSTON, May 19, 2021 PRNewswire -- CNS Pharmaceuticals, Inc. NASDAQ: CNSP CNS or the Company, a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced open enrollment for its potentially pivotal study evaluating the efficacy and safety of Berubicin in the treatment of recurrent GBM. CNS lead product candidate, Berubicin, is a novel anthracycline and the first anthracycline to cross the blood-brain barrier. 